Overall rank by patents
#6,035
of 50,000 tracked assignees
USPTO PatentsView assignee record - 56 granted patents across 4 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).
The verdict
According to USPTO PatentsView, Integrity ranks #6,035 of 50,000 tracked US assignees by granted-patent volume, with 56 patents across 4 technology areas.
USPTO PatentsView assignee plate
Corpus R6035 · US Corporation #6,035 · 56 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Global Blood Therapeutics, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Confluent · near
45 score
Firestone Building P… · near
45 score
Integrity Implants · this assignee
45 score
THE WATT Stopper · near
45 score
Zipline International · near
45 score
3D Lighting Innovati… · lowest
7 score
What this shows Integrity Implants Inc. stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-NARROW, INNOV-PAR, CLAIMS-RICH, TYPE-USCORP, VEL-SURGE, BOOK-FULL. Volume places it #6,035 of 50,000; Innovation Score 44.6/100 sits in the top 25% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Global Blood Therapeutics, Inc. (±0 grants).
Integrity Implants Inc. has been granted 56 US utility patents between 2016 and 2025, placing Integrity Implants Inc. at #6,035 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.1 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Integrity Implants Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Integrity sits between Guangzhou China STAR Optoelectronics Semiconductor Display Technology Co., Ltd. (56 patents, rank #6,030) and JCBD, Llc (56 patents, rank #6,038) - the closest US assignees by grant volume. The composite Innovation Score of 44.6/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 33 grants, compared with 11 in the 2015–2019 window, a +200% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Integrity Implants Inc.'s 17.1 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 4 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
GUANGZHOU CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECHNOLOGY CO., LTD.
56 patents
Global Blood Therapeutics, Inc.
56 patents
HOBART BROTHERS LLC
56 patents
HP PRINTING KOREA CO., LTD.
56 patents
INTERSURGICAL AG
56 patents
INVISAGE TECHNOLOGIES, INC.
56 patents
Insyde Software Corp.
56 patents
JCBD, LLC
56 patents
INTEGRITY IMPLANTS INC.
56 patents
What this shows Integrity holds 56 patents at rank #6,034, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #6,034 in granted patent volume.
Other assignees with the most granted patents in Integrity's primary technology class.
Two PlainPatent-derived peer sets for Integrity, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (45 here).
Nearest assignees by average claims per patent (17.1 here).
Integrity's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
45 Top 25% higher than 75% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 3.6% |
| 2018 | 6 | 10.7% |
| 2019 | 3 | 5.4% |
| 2020 | 6 | 10.7% |
| 2021 | 3 | 5.4% |
| 2022 | 13 | 23.2% |
| 2023 | 7 | 12.5% |
| 2024 | 4 | 7.1% |
| 2025partial year | 12 | 21.4% |
Top 4 of 4 technology areas
Overall rank by patents
#6,035
of 50,000 tracked assignees
44.6 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.